Metonitazene is a hallucinogen and dissociative anesthetic that has been used in scientific research. It is a derivative of methoxetamine and has similar effects to it, though it also carries some unique properties.

Metonitazene is similar in structure to ketamine, but with a different functional group on the amine. It is believed that this difference in functional groups is what causes metonitazene's unique effects on the body and mind.

Metonitazene has been shown to have analgesic properties comparable to morphine without producing respiratory depression, which makes it useful as an analgesic drug for surgeries and other medical procedures where respiratory depression could be dangerous to patients' health.

Metonitazene is a nitrosourea antineoplastic agent used in the management of advanced breast cancer in combination with other drugs.

Metonitazene is indicated for the treatment of metastatic breast cancer in women whose disease has progressed following treatment with other chemotherapeutic agents. It has been shown to inhibit cyclin-dependent kinases (CDKs) and thus to arrest cell cycle progression at the G2/M phase transition.

Metonitazene may produce bone marrow suppression and gastrointestinal toxicity, including nausea and vomiting, which can be severe enough to require interruption of therapy. The most serious side effect associated with metonitazene is bone marrow suppression, which may require blood transfusions or discontinuation of therapy.

The recommended dosage for metonitazene tablets is 1 gm orally once daily as a single dose taken on an empty stomach (at least one hour before or two hours after a meal).